Industry highlights: switching from manual to automated HSC gene engineering [WEBINAR]

For more information, visit: www.miltenyibi... Discover the benefits of transitioning from manual to automated hematopoietic stem cell (HSC) gene engineering using the CliniMACS Prodigy® HSC Engineering process, featuring insights from a case study by Ana Rubio of Orchard Therapeutics.
Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to set industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,900 employees across 24 countries.